JP2016534996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534996A5 JP2016534996A5 JP2016523209A JP2016523209A JP2016534996A5 JP 2016534996 A5 JP2016534996 A5 JP 2016534996A5 JP 2016523209 A JP2016523209 A JP 2016523209A JP 2016523209 A JP2016523209 A JP 2016523209A JP 2016534996 A5 JP2016534996 A5 JP 2016534996A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- administration
- antigen
- binding fragment
- copd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361891175P | 2013-10-15 | 2013-10-15 | |
| US61/891,175 | 2013-10-15 | ||
| US201461970126P | 2014-03-25 | 2014-03-25 | |
| US61/970,126 | 2014-03-25 | ||
| PCT/US2014/060432 WO2015057668A1 (en) | 2013-10-15 | 2014-10-14 | Methods for treating chronic obstructive pulmonary disease using benralizumab |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019132432A Division JP6870037B2 (ja) | 2013-10-15 | 2019-07-18 | ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016534996A JP2016534996A (ja) | 2016-11-10 |
| JP2016534996A5 true JP2016534996A5 (enExample) | 2017-11-16 |
Family
ID=52809872
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523209A Pending JP2016534996A (ja) | 2013-10-15 | 2014-10-14 | ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 |
| JP2019132432A Active JP6870037B2 (ja) | 2013-10-15 | 2019-07-18 | ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 |
| JP2021068065A Pending JP2021107421A (ja) | 2013-10-15 | 2021-04-14 | ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019132432A Active JP6870037B2 (ja) | 2013-10-15 | 2019-07-18 | ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 |
| JP2021068065A Pending JP2021107421A (ja) | 2013-10-15 | 2021-04-14 | ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20150104447A1 (enExample) |
| EP (2) | EP3057609A4 (enExample) |
| JP (3) | JP2016534996A (enExample) |
| KR (1) | KR20160061352A (enExample) |
| CN (2) | CN105636607A (enExample) |
| AU (2) | AU2014334563A1 (enExample) |
| BR (1) | BR112016008082A2 (enExample) |
| CA (1) | CA2925402A1 (enExample) |
| MX (2) | MX2016004329A (enExample) |
| RU (1) | RU2706729C2 (enExample) |
| SG (2) | SG10201807318RA (enExample) |
| WO (1) | WO2015057668A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160068613A1 (en) | 2013-04-29 | 2016-03-10 | Hoffmann-La Roche Inc. | Fc-receptor binding modified asymmetric antibodies and methods of use |
| CA2932364A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with improved protein a-binding |
| JP6895884B2 (ja) | 2015-06-01 | 2021-06-30 | 国立大学法人富山大学 | 肺高血圧症の治療薬及び治療方法 |
| CN109544378B (zh) * | 2018-10-27 | 2024-06-25 | 平安医疗健康管理股份有限公司 | 一种肺源性心脏病资质认证方法、设备及服务器 |
| TW202110479A (zh) * | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| MX2022006812A (es) * | 2019-12-06 | 2022-08-25 | Sanofi Biotechnology | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. |
| EP3957308A1 (en) | 2020-08-21 | 2022-02-23 | Palobiofarma, S.L. | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
| WO2023034993A1 (en) * | 2021-09-03 | 2023-03-09 | Gleich Gerald J | Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997010354A1 (fr) * | 1995-09-11 | 1997-03-20 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine |
| EP1176195B1 (en) * | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2402477A1 (en) * | 2000-02-15 | 2001-08-23 | Kyowa Hakko Kogyo Co., Ltd. | Eosinophil-specific apoptosis inducer |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20060014680A1 (en) * | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| HUE026728T2 (en) * | 2007-05-14 | 2016-06-28 | Medimmune Llc | A method for reducing eosinophil levels |
| CN101249093A (zh) * | 2008-03-19 | 2008-08-27 | 李虎山 | 一种治疗慢性阻塞性肺部疾病的组合物 |
| CA2814431A1 (en) * | 2010-10-15 | 2012-04-19 | Medimmune Limited | Therapies for improving pulmonary function |
| JP6005657B2 (ja) * | 2010-12-16 | 2016-10-12 | ジェネンテック， インコーポレイテッド | Ｔｈ２阻害に関連する診断及び治療 |
| WO2012158954A1 (en) * | 2011-05-18 | 2012-11-22 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| KR20140097217A (ko) * | 2011-11-01 | 2014-08-06 | 메디뮨 엘엘씨 | 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법 |
| RS58711B1 (sr) * | 2013-08-12 | 2019-06-28 | Astrazeneca Ab | Postupci za povećanje forsiranog ekspiratornog volumena kod asmatičara korišćenjem benralizumaba |
| WO2015023504A1 (en) * | 2013-08-12 | 2015-02-19 | Medlmmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| EP3033103B1 (en) * | 2013-08-12 | 2019-06-05 | AstraZeneca AB | Methods for improving asthma symptoms using benralizumab |
-
2014
- 2014-10-14 CN CN201480056549.0A patent/CN105636607A/zh active Pending
- 2014-10-14 EP EP14853201.3A patent/EP3057609A4/en not_active Withdrawn
- 2014-10-14 JP JP2016523209A patent/JP2016534996A/ja active Pending
- 2014-10-14 US US14/513,866 patent/US20150104447A1/en not_active Abandoned
- 2014-10-14 SG SG10201807318RA patent/SG10201807318RA/en unknown
- 2014-10-14 WO PCT/US2014/060432 patent/WO2015057668A1/en not_active Ceased
- 2014-10-14 KR KR1020167009675A patent/KR20160061352A/ko not_active Ceased
- 2014-10-14 RU RU2016118425A patent/RU2706729C2/ru active
- 2014-10-14 BR BR112016008082A patent/BR112016008082A2/pt not_active Application Discontinuation
- 2014-10-14 CA CA2925402A patent/CA2925402A1/en not_active Abandoned
- 2014-10-14 SG SG11201601807XA patent/SG11201601807XA/en unknown
- 2014-10-14 MX MX2016004329A patent/MX2016004329A/es unknown
- 2014-10-14 AU AU2014334563A patent/AU2014334563A1/en not_active Abandoned
- 2014-10-14 EP EP18189626.7A patent/EP3485902A1/en not_active Withdrawn
- 2014-10-14 CN CN202110508239.XA patent/CN113230399A/zh active Pending
-
2016
- 2016-04-04 MX MX2019013468A patent/MX2019013468A/es unknown
- 2016-05-31 US US15/168,711 patent/US20170107291A1/en not_active Abandoned
-
2017
- 2017-11-29 US US15/825,526 patent/US20180291108A1/en not_active Abandoned
-
2019
- 2019-05-24 US US16/422,212 patent/US20200123262A1/en not_active Abandoned
- 2019-07-18 JP JP2019132432A patent/JP6870037B2/ja active Active
-
2020
- 2020-04-02 AU AU2020202333A patent/AU2020202333A1/en not_active Abandoned
-
2021
- 2021-04-14 JP JP2021068065A patent/JP2021107421A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534996A5 (enExample) | ||
| Lugogo et al. | Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study | |
| Thibodeaux et al. | A review of dupilumab in the treatment of atopic diseases | |
| Dahl et al. | Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study | |
| Mukherjee et al. | Anti-IL5 therapy for asthma and beyond | |
| Wedzicha et al. | Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients | |
| ES2716906T3 (es) | Métodos para reducir la tasa de exacerbación de asma mediante el uso de benralizumab | |
| Fala | Ofev (Nintedanib): first tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis | |
| JP2016513640A5 (enExample) | ||
| Bateman et al. | Recent advances in COPD disease management with fixed-dose long-acting combination therapies | |
| D'Urzo et al. | A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease | |
| Mkorombindo et al. | Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease | |
| Hanania et al. | Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD | |
| Donohue et al. | One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD | |
| JP2014513121A5 (enExample) | ||
| JP2013525310A5 (enExample) | ||
| JP2014520874A5 (enExample) | ||
| RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина | |
| Mathioudakis et al. | Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent? | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| Gulati et al. | Bringing stability to the chronic obstructive pulmonary disease patient: clinical and pharmacological considerations for frequent exacerbators | |
| Kelleher et al. | Absorption, distribution, metabolism, and elimination (ADME) of umeclidinium (UMEC) in healthy adults | |
| JP2017514829A5 (enExample) | ||
| Singh et al. | Biological therapy in COPD management: current evidence, challenges and opportunities | |
| Colice | Emerging therapeutic options for asthma |